Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Antoine Desilets"'
Autor:
Arielle Elkrief, Eder Orlando Méndez-Salazar, Jade Maillou, Chad M. Vanderbilt, Pooja Gogia, Antoine Desilets, Meriem Messaoudene, Daniel Kelly, Marc Ladanyi, Matthew D. Hellmann, Laurence Zitvogel, Charles M. Rudin, Bertrand Routy, Lisa Derosa, Adam J. Schoenfeld
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-9 (2024)
Abstract Anti-PD(L)-1 inhibition combined with platinum doublet chemotherapy (Chemo-IO) has become the most frequently used standard of care regimen in patients with non-small cell lung cancer (NSCLC). The negative impact of antibiotics on clinical o
Externí odkaz:
https://doaj.org/article/6b78137517bb4690816d94fa12584591
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 10, Pp n/a-n/a (2024)
Abstract The ROS1 proto‐oncogene encodes a receptor tyrosine kinase with structural homology to other oncogenic drivers, including ALK and TRKA‐B‐C. The FDA‐approved tyrosine kinase inhibitors (TKIs) crizotinib and entrectinib have demonstrat
Externí odkaz:
https://doaj.org/article/b3703d2d6ea4452c8c1316b4b0921905
Autor:
Antoine Desilets, MD, MSc, Gabryella Pinheiro, PhD, Wiam Belkaid, PhD, Olivier Salko, MD, Julie Malo, Eleyine Zarour, MD, Adeline Jouquan, MSc, Anne-Julie Thibaudeau, MSc, Marc-Antoine Nolin, MSc, John Stagg, PhD, Marie Florescu, MD, Mustapha Tehfe, MD, Normand Blais, MD, MSc, Samer Tabchi, MD, Jean Chalaoui, MD, Philippe Stephenson, MD, Arielle Elkrief, MD, Vincent Quoc-Huy Trinh, MD, MSc, Bertrand Routy, MD, PhD, Moishe Liberman, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 12, Pp 100737- (2024)
Introduction: NSCLC is the leading cause of cancer-related mortality. Although immune-checkpoint inhibitors (ICIs) have improved survival in patients with advanced NSCLC, treatment resistance remains a challenge. Cryoactivation, a technique inducing
Externí odkaz:
https://doaj.org/article/f11731bcb8a4444d878c7e52e5ba0d56
Autor:
Antoine Desilets, Alan L Ho
Publikováno v:
BMJ Oncology, Vol 2, Iss 1 (2023)
Externí odkaz:
https://doaj.org/article/8e86894ad91041b8b40e1929c290edd7
Autor:
Antoine Desilets, William McCarvill, Francine Aubin, Houda Bahig, Olivier Ballivy, Danielle Charpentier, Édith Filion, Rahima Jamal, Louise Lambert, Phuc Felix Nguyen-Tan, Charles Vadnais, Xiaoduan Weng, Denis Soulières
Publikováno v:
Current Oncology, Vol 29, Iss 2, Pp 497-509 (2022)
Background: 5-FU-based chemoradiotherapy (CRT) could be associated with severe treatment-related toxicities in patients harboring at-risk DPYD polymorphisms. Methods: The studied population included consecutive patients with locoregionally advanced o
Externí odkaz:
https://doaj.org/article/6ec9f5741873491ea64eb5b36e2b18a2
Autor:
Corentin Richard, Bertrand Routy, Myriam Benlaifaoui, Omar El Ouarzadi, Khoudia Diop, Antoine Desilets, Julie Malo, Wiam Belkaid, Andréanne Leblanc, Julien Lamontagne, Meriem Messaoudene, Arielle Elkrief
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/e6283b609efd44a689f967c76ab118bc
Autor:
Antoine, Desilets, Denis, Soulières
Publikováno v:
The Cancer Journal. 28:369-376
The phosphoinositide 3-kinase (PI3K) pathway is aberrantly activated in most head and neck squamous cell carcinomas, making it a prized target for targeted therapy development. Multiple PI3K inhibitors have been studied in early phase trials, with un
Autor:
Antoine Desilets, Alan L. Ho
Publikováno v:
The Cancer Journal. 28:363-368
Autor:
Antoine Desilets, Arielle Elkrief
Publikováno v:
Current Opinion in Oncology.
Autor:
Laurence Zitvogel, Guido Kroemer, Safae Terrisse, Romain Daillère, Antoine Desilets, Bertrand Routy, Lisa Derosa
Supplementary Table S3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bf7d9f42ec2c18f4f7ddecc10023d79
https://doi.org/10.1158/2159-8290.22540042.v1
https://doi.org/10.1158/2159-8290.22540042.v1